Mechanistic Insights into SFI’s Inhibition of Glioma Growth: SRC/PI3K/AKT Pathway Targeting via Network Pharmacology

Study Background and Research Question

Gliomas are the most common and aggressive primary brain tumors, accounting for 30–50% of such malignancies and presenting significant challenges in clinical management due to rapid proliferation, invasion, and resistance to conventional therapies. Despite advances in surgery, radiotherapy, and chemotherapy, patient survival remains poor, with median overall survival often under 17 months. The urgent need for novel therapeutic strategies has driven interest in multi-component approaches such as traditional Chinese medicine (TCM), which may exert anti-tumor effects through complex network interactions. Shenqi Fuzheng injection (SFI), a TCM formulation primarily composed of Codonopsis pilosula and Astragalus membranaceus, is already used as an adjuvant in cancer chemotherapy, but its precise molecular mechanism in glioma treatment has remained unclear.

Key Innovation from the Reference Study

The study by Li et al. (DOI:10.1016/j.jep.2024.118128) innovatively applies network pharmacology to interrogate the molecular underpinnings of SFI’s effects on glioma cells. By integrating computational target prediction with experimental validation, the research identifies the SRC/PI3K/AKT signaling axis as a central mediator of SFI’s anti-glioma activity. This systems-level approach not only elucidates the probable mechanisms of SFI but also bridges the gap between empirical TCM use and modern molecular oncology—an advancement over reductionist, single-target studies.

Methods and Experimental Design Insights

The investigation adopted a multi-tiered strategy:

• Network Pharmacology Analysis: Active SFI components were identified and their putative protein targets predicted using databases and literature mining. The overlap between these targets and known glioma-related molecular networks was mapped, revealing 79 shared targets among 110 SFI-related and 3,343 glioma-associated proteins.
• In Vitro Assays: The effects of SFI were tested on human glioma U87 and T98G cell lines. Cell proliferation was assessed using CCK-8 and EdU incorporation assays. Migration and invasion capacities were measured by scratch and Transwell assays, while cell cycle distribution was determined via flow cytometry. Western blot and immunofluorescence analyses quantified changes in pathway and EMT marker proteins.
• In Vivo Validation: A subcutaneous GL261 murine glioma model was used to evaluate SFI’s anti-tumor efficacy, with tumor growth assessed by histology (HE staining) and immunohistochemistry.

This integrative pipeline allowed for both the identification of candidate pathways and their experimental verification, strengthening the causal inference between SFI administration and glioma suppression.

Core Findings and Why They Matter

Key findings from the study include:

• Proliferation Inhibition: SFI significantly suppressed proliferation in U87 and T98G glioma cells, inducing S-phase cell cycle arrest.
• Migration and EMT Suppression: SFI reduced glioma cell migration and invasion, accompanied by downregulation of epithelial-mesenchymal transition (EMT) markers, which are associated with metastatic potential.
• In Vivo Tumor Growth Reduction: In a GL261 mouse model, SFI-treated animals exhibited markedly decreased tumor growth, supporting the clinical relevance of the in vitro findings.
• SRC/PI3K/AKT Pathway Involvement: Network pharmacology and Western blot analyses converged on the SRC/PI3K/AKT pathway as a principal mediator of SFI’s anti-glioma effects, suggesting that SFI may exert its action by blocking this critical signal transduction axis.

These results provide mechanistic clarity on how botanical multi-component therapies like SFI can disrupt tumor-promoting signaling networks, supporting its further exploration as an anti-angiogenic compound and angiogenesis inhibitor in tumor angiogenesis research.

Comparison with Existing Internal Articles

Internal articles such as "Network Pharmacology Reveals SFI's Role in Blocking Glioma Progression" and "Network Pharmacology Uncovers SFI's Anti-Glioma Mechanisms via SRC/PI3K/AKT" corroborate the main findings of the reference paper, emphasizing SFI’s suppression of glioma proliferation and migration through the SRC/PI3K/AKT pathway. Both internal resources highlight the value of integrating computational and experimental approaches to clarify the multi-level anti-angiogenic and anti-metastatic actions of SFI. The current reference study advances this field by providing more extensive in vivo validation and a larger target network mapping, thus strengthening the evidence base for SFI’s application in preclinical tumor models.

Limitations and Transferability

Despite its strengths, the study presents several limitations:

• Component Complexity: SFI contains numerous bioactive constituents, but the contribution of individual compounds to the observed effects was not dissected.
• Model Constraints: The in vivo experiments were limited to subcutaneous GL261 mouse models, which may not fully recapitulate the clinical behavior of human gliomas.
• Pathway Specificity: While the SRC/PI3K/AKT pathway was identified as central, the possibility of additional, parallel anti-angiogenic mechanisms remains open.

Transferability to other tumor types or human clinical scenarios will require cautious extrapolation and further validation.

Protocol Parameters

• SFI in vitro treatment: Apply to U87 and T98G glioma cells; titrate concentration based on CCK-8 assay viability curves for optimal S-phase arrest.
• Migratory inhibition assessment: Utilize scratch and Transwell assays post-SFI exposure to quantify changes in migration/invasion.
• In vivo dosing: Administer SFI to C57BL/6 mice bearing GL261 tumors; reference original study for detailed injection schedule and dosing.
• Western blot target validation: Assess SRC, PI3K, and AKT phosphorylation status following SFI intervention.

Research Support Resources

For researchers seeking to dissect anti-angiogenic mechanisms or to model tumor angiogenesis inhibition in vitro or in vivo, small-molecule VEGF receptor inhibitors such as AAL-993 (SKU C3730) from APExBIO offer precise and selective targeting of VEGFR-1, VEGFR-2, and VEGFR-3. As reported in the internal article, AAL-993 enables robust modeling of tumor angiogenesis and can complement studies exploring the intersection of VEGF and SRC/PI3K/AKT pathways. Researchers are encouraged to refer to product specifications and to align usage with established protocols for optimal reproducibility.